The effect of adjuvants on the immune response induced by a DBL4[varepsilon]-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria

Highlights * Antibodies against the DBL4[varepsilon]-ID4 subunit of the VAR2CSA protein can inhibit parasite binding to the placental ligand chondroitin sulphate A. * We tested the ability of DBL4[varepsilon]-ID4 to induce binding-inhibitory antibodies when formulated with adjuvants approved for hum...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-01, Vol.30 (3), p.572
Main Authors: Pinto, VV, Salanti, A, Joergensen, LM, Dahlbäck, M, Resende, M, Ditlev, SB, Agger, EM, Arnot, DE, Theander, TG, Nielsen, MA
Format: Article
Language:English
Subjects:
Agreements
Bias
Clinical trials
Erythrocytes
Immune response
Malaria
Mineral oils
Parasites
Proteins
Studies
Vaccines
Vector-borne diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights * Antibodies against the DBL4[varepsilon]-ID4 subunit of the VAR2CSA protein can inhibit parasite binding to the placental ligand chondroitin sulphate A. * We tested the ability of DBL4[varepsilon]-ID4 to induce binding-inhibitory antibodies when formulated with adjuvants approved for human use. * We have characterized the immune response of DBL4[varepsilon]-ID4 in combination with Freund's adjuvant, Montanide®ISA 720, Alhydrogel®and CAF01. * The results demonstrate that the DBL4[varepsilon]-ID4 antigen is highly immunogenic and that binding inhibitory antibodies are induced when formulated with any of the tested adjuvants.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.11.068